Innovative Approach to Improve Quality of Life Post-Stem Cell Transplantation
A recent study published in the June 2024 issue of JNCCN—Journal of the National Comprehensive Cancer Network highlights a promising new approach for alleviating anxiety and enhancing the quality of life in patients undergoing hematopoietic stem cell transplantation (HSCT). This pilot study, conducted by researchers at Brigham and Women’s Hospital and Dana-Farber Cancer Institute, explored […]
Stem Cell Strategies for Sickle Cell Cure
Welcome to our article on stem cell approaches for sickle cell anemia treatment. Sickle cell disease (SCD) affects thousands of Americans and millions worldwide, primarily those of African descent. Unfortunately, it remains an incurable condition for most individuals. However, there is hope in the form of stem cell strategies that offer the potential for a […]
Hematopoietic Stem Cell Transplantation (HSCT) for Leukemia: A Modern Lifeline
When faced with leukemia, a type of cancer that launches a stealthy and devastating attack on the body’s blood-forming tissues, patients and their families often feel as though they’ve been cast adrift in a tempestuous sea. However, amidst these turbulent waters, Hematopoietic Stem Cell Transplantation (HSCT) emerges as a life-saving beacon of hope, offering a […]
Clinical Applications of Hematopoietic Stem Cells in Blood Cell Disorders
Welcome, dear readers, to our exploration of the fascinating world of stem cells. Today, we’re diving deep into a specific type of stem cell, known as the hematopoietic stem cell. Picture these cells as the master builders of our blood system, the architects that design and construct the various types of cells that flow through […]
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
MIAMI, Feb. 16, 2023 (GLOBE NEWSWIRE) — Helocyte, Inc., (“Helocyte”) a subsidiary company of Fortress Biotech, Inc. (Nasdaq: FBIO), announced today that data from a Phase 1 pilot trial (see NCT03560752) evaluating the potential safety, immunological response and efficacy of the cytomegalovirus (“CMV”) vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic […]
First US leukemia patient dosed with Smart Immune’s investigational SMART101 cell therapy
Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell therapy platform to fully and rapidly re-arm the immune system, announced today that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial Sloan Kettering Cancer Center (MSK). The Phase […]